At MIT Forefront, panelists discuss health care and work during a pandemic — and the role for business where government falls short.
Biological engineer discusses condensing the time taken to develop therapeutics down from many years to a matter of months.
Researchers have designed a simple, low-cost device for subcutaneous injection of viscous formulations.
Sequential immunization might be safer and more effective than the existing tetravalent vaccine.
The experimental drug has shown promise in early-stage clinical trials conducted in Singapore.
In lab tests, virus-like DNA structures coated with viral proteins provoke a strong immune response in human B cells.
The startup macro-eyes uses artificial intelligence to improve vaccine delivery and patient scheduling.
Manufacturability is key to producing a widely available, affordable vaccine.
Specialized dye, delivered along with a vaccine, could enable “on-patient” storage of vaccination history.
During the community flu clinic on Oct. 3, at least 9,378 people on campus had received vaccinations — an average of one shot every 3.8 seconds.
Vaccines packaged in novel nanoparticles could offer a new way to fight cancer and infectious diseases.
Researchers apply network theory to HIV protein structure, uncovering a vital link between connectivity and protective immune response.